Stock Taper
EARNINGS CALL ARCHIVE 1 CALL ON FILE
ENTA — Enanta Pharmaceuticals, Inc.
NASDAQ
FULL STOCK PAGE →

Q2 2024 Earnings Call Summary

MAY 6, 2024
REVENUE
$17.1M -5.3%
NET MARGIN
-182.7% +2.9 PTS
EPS
-$1.47 +7.0%
FREE CASH FLOW
-$30.3M -17.4%

No summary has been written for this call yet.